Avivagen Inc. Announces Stock Option Grants
Avivagen Inc. (TSXV:VIV) has approved the issuance of 577,500 stock options to its officers, directors, consultants, and employees. These options will vest over an eight-quarter period and are exercisable within five years at a strike price of $0.56. This issuance forms part of the total remuneration package for these individuals. Additionally, the grants are subject to approval from the TSX Venture Exchange. Avivagen focuses on products for livestock, companion animals, and human health, leveraging its OxC-beta™ technology to promote immune function and improve health economically.
- Issuance of 577,500 stock options enhances employee retention and motivation.
- Options granted are competitively priced at a strike price of $0.56.
- None.
Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”) announces that its Board of Directors has approved the issuance of 577,500 stock options granted to officers, directors, consultants and employees of the Corporation. The options, which shall be vested over an eight-quarter period, are exercisable up to five years from the issuing date and have a strike price of
Option grants are subject to approval of the TSX Venture Exchange.
For further information on Avivagen's public disclosure file, consult SEDAR at www.sedar.com.
About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications. By unlocking an overlooked facet of β-carotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals. Avivagen is a public corporation traded on the TSX Venture Exchange under the symbol VIV and on the OTCQB Exchange in the U.S. under the symbol VIVXF, and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Taiwan, New Zealand, Thailand, Mexico, Brazil, Australia and Malaysia.
Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements set out in this news release relating to the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as growth promoters are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics as growth promoters in livestock feeds due to many factors, many of which are outside of Avivagen’s control. Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen’s most recent management’s discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright © 2021 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005691/en/
FAQ
What are the details of Avivagen's stock options issuance?
What is the significance of the stock options approved by Avivagen on TSXV:VIV?
When are the stock options for Avivagen expected to vest?
What is the purpose of Avivagen's OxC-beta™ technology?
